批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2020/08/20 |
SUPPL-6(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/02/26 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/02/26 |
SUPPL-2(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2010/11/29 |
ORIG-1(原始申请) |
Approval |
|
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:TOPOTECAN HYDROCHLORIDE 剂型/给药途径:INJECTABLE;INJECTION 规格:EQ 4MG BASE/VIAL 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020671 |
001 |
NDA |
HYCAMTIN |
TOPOTECAN HYDROCHLORIDE |
INJECTABLE;INJECTION |
EQ 4MG BASE/VIAL |
Prescription |
Yes |
Yes |
AP |
1996/05/28
|
SANDOZ |
091089 |
001 |
ANDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
INJECTABLE;INJECTION |
EQ 4MG BASE/VIAL |
Prescription |
No |
No |
AP |
2010/11/29
|
FRESENIUS KABI USA |
091199 |
001 |
ANDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
INJECTABLE;INJECTION |
EQ 4MG BASE/VIAL |
Prescription |
No |
No |
AP |
2010/12/01
|
TEYRO LABS |
090620 |
001 |
ANDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
INJECTABLE;INJECTION |
EQ 4MG BASE/VIAL |
Prescription |
No |
No |
AP |
2010/12/02
|
ACTAVIS TOTOWA |
091284 |
001 |
ANDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
INJECTABLE;INJECTION |
EQ 4MG BASE/VIAL |
Prescription |
No |
No |
AP |
2011/01/26
|
SAGENT PHARMS |
201191 |
001 |
ANDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
INJECTABLE;INJECTION |
EQ 4MG BASE/VIAL |
Prescription |
No |
No |
AP |
2011/03/09
|
DR REDDYS LABS LTD |
202351 |
001 |
ANDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
INJECTABLE;INJECTION |
EQ 4MG BASE/VIAL |
Prescription |
No |
No |
AP |
2013/06/26
|
ACCORD HLTHCARE |
206962 |
001 |
ANDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
INJECTABLE;INJECTION |
EQ 4MG BASE/VIAL |
Prescription |
No |
No |
AP |
2016/11/30
|
NOVAST LABS |